Elçin YÖRÜKOĞLU, Betül OKUYAN, Mesut SANCAR, Fikret İZZETTİN

Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üzerine etkisinin değerlendirilmesi

Amaç: Bu çalışmada, alendronat kullanan senil osteoporozlu kadınlarda alendronat tedavisinin idrar kalsiyum/kreatinin oranları üzerine etkisinin değerlendirilmesi amaçlanmıştır.Yöntem: Bu amaçla, tedavi öncesi ve 3 aylık tedavi sonrasında hastaların idrar kalsiyum/kreatinin oranları ölçülmüş ve ayrıca serum kalsiyum, fosfor, alkalen fosfataz (ALP), paratiroid hormon (PTH) değerlerinin sonuçları değerlendirilmiştir.Bulgular: 3 aylık tedaviden sonra idrar kalsiyum/kreatinin oranında ve serum ALP, kalsiyum ve fosfor düzeylerinde istatistiksel olarak anlamlı bir düşüş ve serum PTH düzeyinde de bu değişikliklere cevap olarak anlamlı yükselme görülmüştür (p<0.05).Sonuç: Tedavi başlangıcında osteoporoz hastalarının tedavi etkinliğinin ve uyuncunun değerlendirilmesi için idrar kalsiyum/kreatinin oranının izlem parametresi olarak kullanılabileceği sonucuna varılmıştır. Anahtar Kelimeler: Alendronat, osteoporoz, idrar kalsiyum/kreatinin oranı

Anahtar Kelimeler:

Alendronat, osteoporoz, idrar kalsiyum/kreatinin oranı

Assesment of the effect of alendronate therapy on urine calcium/creatinine ratio in patients with senil osteoporosis

Objective: In this study, it is aimed to assess the effects of alendronate treatment on urinary calcium/creatinine ratio in female patients newly diagnosed as senile osteoporosis and prescribed alendronate treatment.Method: According to this aim, urinary calcium/creatinine ratio were measured at baseline and after 3 months alendronate therapy and also the levels of serum calcium , phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH) were evaluated.Results: Statistically significant decreases in serum ALP, calcium and phosphorus levels and urinary calcium/creatinine ratio were observed and as a response to these alterations, serum PTH levels were increased significantly after three months therapy (p<0.05).Conclusion: It was found that urinary calcium/creatinine ratio can be used in evaluation of treatment efficacy and adherence of patients with osteoporosis at the beginning of the therapy.

Keywords:

-,

PDF

___

Yanık B, Atalar H, Külcü DG, Gökmen D. Postmenopozal Kadınlarda Vücut Kütle İndeksinin Kemik Mineral Yoğunluğuna Etkisi. Osteoporoz Dünyasından. 2007; 13: 56-59.
O’Connell MB, Vondracek SF. Osteoporosis and Other Metabolic Bone Diseases. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy APathophysiologic Approach. 7th ed. McGraw- Hill Companies; 2008, p.1483-1504.
Garnero P. Markers of Bone Turnover for Monitoring Antiresorptive Treatment of Osteoporosis. Journal für Menopause. 2000; 7 (Suppl 2): 49-51.
Küçük S, Gökdeniz R, Atmaca R, Uryan İ, Buhur A, Taşkın Ö. Effect of etidronate on urinary calcium/creatinin ratio in postmenopausal women: a prospective, randomized, placebo controlled study. Tr J of Medical Sciences. 1999; 29: 683-687.
Bartl R, Frisch B. Osteoporosis: Diagnosis, Prevention, Therapy. Çeviren (Ed): Tan AA Osteoporoz Teşhis, Korunma, Tedavi. Ankara: Orta Doğu Reklam Tanıtım ve Yayıncılık A.Ş. Türkiye Klinikleri Yayın; 2006, p.128-143.
Russell RG:. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068:367-401.
Bonnick S, Saag KG, Kiel PD. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91: 2631-2637.
Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta. 2001; 313 (1-2): 95-105.
Eastell R., Hannon RA. Biochemical markers of bone turnover. In: Lobo RA, eds. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. San Diego, California: Elsevier Academic Press; 2007, p.337- 349.
Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006; 119 (Suppl 1): 25-31.
Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 1999; 24 (6): 603-609.
Chesnut CH 3rd, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int. 1993; 3 (Suppl 3): 17-19.
Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland- Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13 (9): 1431-1438.
Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double- blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005; 90 (5): 2762-2767.
Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H. A placebo- controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J. 1998: 45 (2): 191-201.
McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 1998; 128 (4): 253-261.
Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001; 38 (6): 608-623.
Choi HJ, Im JA, Kim SH. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas. 2008; 60 (2): 170-176.
D’Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010; 21(10): 1741-1750.
Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int. 1989; 44 (2): 74-79.
Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006; 1092: 385-396.
Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999; 45 (8):1353-1358.
Haspolat K, Boşnak M. Çocuklarda osteoporoz. Türkiye Klinikleri Fiziksel Tıp ve Rehabilitasyon Dergisi. 2002; 2 (1): 40-51.